Cloud-native healthcare technology company SOPHiA GENETICS (NASDAQ: SOPH), announced on Thursday the launch of SOPHiA DDM Digital Twins, a research technology designed to create dynamic virtual representations of individual patients.

The technology uses each patient's clinical, biological, imaging and genomic data to generate computational replicas that simulate treatment responses, disease trajectories and survival outcomes.

SOPHiA DDM Digital Twins leverages a multimodal, longitudinal dataset from the SOPHiA GENETICS community in an effort to enable in silico experimentation and hypothesis testing across institutional and geographic boundaries.

The research use only tool generates synthetic data that mirrors real-world disease patterns and continuously refines its models as new data are added.

SOPHiA GENETICS says that the system could, in the future, help oncologists explore treatment strategies, match patients to likely effective therapies and reduce exposure to ineffective or unsuitable treatments, avoiding unnecessary side effects and financial expense.

SOPHiA DDM Digital Twins will initially launch on the SOPHiA DDM Platform for lung cancer, with additional cancer types expected to follow in coming months.